Indian Pharmacopoeia 2026 Introduces Over 3,300 Standards to Strengthen Medicine Safety

The Indian Pharmacopoeia Commission (IPC) has released the 10th edition of the Indian Pharmacopoeia (IP-2026), featuring 3,340 quality standards to ensure safe and effective medicines in India. The edition, launched by Union Health Minister J.P. Nadda on January 2, 2026, is available in both hardbound and online formats.

IP-2026 covers key therapeutic areas, including anti-tuberculosis, anti-diabetic, anti-cancer medicines, iron supplements, and national health programme drugs. It introduces 121 new monographs, spanning drug substances, dosage forms, vitamins, minerals, biotechnology-derived products, vaccines, blood and blood components, and veterinary vaccines. Five new general chapters have been added, while 18 general chapters and 22 excipient monographs have been harmonized with international pharmacopoeias (USP, EP, JP).

Notably, 22 monographs on blood and its components—including red cells, plasma, platelets, and granulocytes—are introduced or revised, enhancing standards for irradiation, preparation, and storage. IP-2026 continues India’s effort to align with global quality benchmarks and ensure patient safety.

06-01-2026